EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026

EpiCast Report: Chronic Kidney Disease - Epidemiology Forecast to 2026

Summary

Chronic kidney disease (CKD), or chronic renal disease, is an asymptomatic, long-term condition that damages the kidneys and leads to the loss of kidney function over time (NIH, 2010). As the disease progresses, the symptoms worsen, eventually leading to kidney failure (NIH, 2010). The glomerular filtration rate (GFR), a key measure of kidney function, is determined by the amount of creatinine in the blood, and the Kidney Disease, Improving Global Outcomes (KDIGO) classification system is considered the standard for GFR measurement and diagnosis of CKD.

GlobalData epidemiologists provide a 10-year epidemiological forecast for the total prevalent cases (including both diagnosed and undiagnosed cases) of CKD Stages I-IV by age and sex, the total prevalent cases of CKD by stage, the diagnosed prevalent cases of CKD Stages I-V, and the diagnosed prevalent cases of CKD by stage.

In the 7MM, GlobalData epidemiologists forecast the diagnosed prevalent cases of CKD, Stages I-V, to increase from 25,775,828 cases in 2016 to 28,325,839 cases in 2026, at an Annual Growth Rate (AGR) of 0.99%. The UK will have the highest number of diagnosed cases of CKD throughout the forecast period.

Scope

- The Chronic Kidney Disease EpiCast Report provides an overview of the risk factors and global trends of chronic kidney disease in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).
- This report also includes a 10-year epidemiological forecast for the total prevalent cases of CKD, Stages I-IV, segmented by age (beginning at 20 years and ending at ages 80 years and older), by sex, and by stage. Furthermore, this report includes a forecast of the diagnosed prevalent cases of CKD, Stages I-V, and the diagnosed prevalent cases of CKD by stage.
- The chronic kidney disease epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy

The Chronic Kidney Disease EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global chronic kidney disease treatment market.
- Quantify patient populations in the chronic kidney disease market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for chronic kidney disease therapeutics in each of the markets covered.
- Understand magnitude of chronic kidney disease.

. List of Tables 3
. List of Figures 3
Chronic Kidney Disease: Executive Summary 4
. Related Reports 5
. Upcoming Reports 6
3 Epidemiology 7
3. Disease Background 7
3. Risk Factors and Comorbidities 8
3.3 Global and Historical Trends 8
3.4 Forecast Methodology 9
3.4. Sources 0
3.4. Forecast Assumptions and Methods 4
3.5 Epidemiological Forecast for CKD (06-06) 0
3.5. Total Prevalent Cases of CKD, Stages I-IV 0
3.5. Age-Specific Total Prevalent Cases of CKD, Stages I-IV 0
3.5.3 Sex-Specific Total Prevalent Cases of CKD, Stages I-IV
3.5.4 Total Prevalent Cases of CKD by Stage
3.5.5 Diagnosed Prevalent Cases of CKD, Stages I-V 3
3.5.6 Diagnosed Prevalent Cases of CKD by Stage 4
3.6 Discussion 5
3.6. Epidemiological Forecast Insight 5
3.6. Limitations of the Analysis 6
3.6.3 Strengths of the Analysis 6
4 Appendix 7
4. Bibliography 7
4. About the Authors 9
4.. Epidemiologists 9
4.. Reviewers 9
4..3 Global Director of Therapy Analysis and Epidemiology 30
4..4 Global Head and EVP of Healthcare Operations and Strategy 3
4.3 About GlobalData 3
4.4 Contact Us 3
4.5 Disclaimer 3

List Of Tables

1.1 List of Tables
Table 1: KDIGO Classification of CKD 7
Table 2: Risk Factors and Comorbidities for CKD 8
Table 3: 7MM, Total Prevalent Cases of CKD, Stages I-IV, Both Sexes, Ages 20 Years, N, Selected Years from 2016-2026 20
Table 4: 7MM, Diagnosed Prevalent Cases of CKD, Stages I-V, Both Sexes, Ages 20 Years, N, Selected Years from 2016-2026 24

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Select Country Albania Algeria Afghanistan Angola Argentina Armenia Aruba Australia Austria Azerbaijan Andorra Anguilla Bahrain Bangladesh Barbados Belarus Belgium Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Brazil Brunei Bulgaria Burkina Faso Burundi Bosnia Cambodia Cameroon Central African Republic Chad Chile China Colombia Comoros Congo (Brazzaville) Cook Islands Costa Rica Cote d Ivoire Croatia Cuba Cyprus Czech Republic Cayman Islands Denmark Djibouti Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Fiji Finland France Gabon Gambia Georgia Germany Ghana Gibraltar Greece Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Honduras Hong Kong Hungary Herzegovina Iceland India Indonesia Iran Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kuwait Korea Kyrgyzstan Laos Latvia Lebanon Lesotho Liberia Libya Lithuania Luxembourg Liechtenstein Macau Macedonia Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Mauritania Mauritius Mexico Moldova Monaco Mongolia Montenegro Morocco Mozambique Myanmar Middle East & North Africa (MENA) Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria North Korea Norway Oman Pakistan Palau Palestinian Territories Panama Papua New Guinea Paraguay Peru Philippines Poland Portugal Puerto Rico Palestine Qatar Romania Russia Rwanda Samoa Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Korea Spain Sri Lanka Saint Kitts and Nevis Saint Vincent and the Grenadines Sudan Suriname Swaziland Sweden Switzerland Syria Scotland San Marino Taiwan Tajikistan Tanzania Thailand Timor-Leste Togo Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States of America Uruguay Uzbekistan Uraguay Vanuatu Venezuela Vietnam Virgin Islands Yemen Zambia Zimbabwe Canada Grenada Cape Verde Belize Curacao Republic of Srpska Antigua and Barbuda Saint Lucia Falkland Islands Faroe Islands Federated States of Micronesia Guadeloupe Martinique Montserrat Niue

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

There is no Reviews available